Eli Lilly and Co (LLY.US) CEO: Its Alzheimer's drugs can play a "preventive" role.
Eli Lilly and Co's CEO told the United Kingdom Health Minister that their method of treating Alzheimer's disease can 'prevent' the disease.
Eli Lilly CEO Told UK Health Secretary Its Alzheimer's Treatment Could "Prevent" Disease: FT
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
Boasting A 54% Return On Equity, Is Eli Lilly and Company (NYSE:LLY) A Top Quality Stock?
Eli Lilly and Company (LLY): Among the Most Promising Growth Stocks According to Hedge Funds
Streetwise: Snack Slump Hits Big Food. Blame Prices, Not Obesity Meds. -- Barron's
US stocks closed: on the two-year anniversary of this bull market, the S&P and Dow hit new highs, while Chinese stocks collectively strengthened.
①The s&p 500 index welcomes the second anniversary of the bull market, historically breaking through the 5800-point integer mark for the first time on Friday; ②The nasdaq china golden dragon index has closed higher for two consecutive days; ③Tesla tumbled by 8%, while uber technologies and Lyft strengthened; ④Boeing announced a 10% workforce reduction.
Express News | US FDA Seeks to Reconsider Decision Preventing Drug Compounders From Selling Versions of Lilly's Weight Loss, Diabetes Drugs
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
U.S. Stocks Move | Weight-loss drug Zepbound is expected to be approved in Japan next year. eli lilly and co (LLY.US) rose more than 1%.
On Friday, eli lilly and co (LLY.US) stock price fluctuated upwards, as of the time of publication, rose by 1.18%, to $921.435.
Street Color: Eli Lilly's Zepbound Expected to Receive Japan Approval in 2025, Nikkei Asia Reports
Zealand Pharma is developing a new generation of obesity drug substitutes.
Danish biotechnology company Zealand Pharma is targeting the "next generation" of weight loss drugs. Meanwhile, competitors from various backgrounds are pouring into this weight loss drug market dominated by heavyweight companies novo-nordisk a/s and eli lilly and co. Zealand Pharma CEO Adam Steensberg stated that compared to traditional glp-1 receptor agonist treatment methods, early trials indicate that their experimental weight loss injection has higher weight loss quality - with less muscle loss and fewer side effects. He added that the company is now looking for a global pharmaceutical company to partner with.
Express News | Japanese Government on Track to Approve of Eli Lilly's Popular Obesity Treatment Zepbound in Coming Months, Head of Co Says - Nikkei
Update: Senator Warren Asks US Antitrust Regulator to 'Carefully Scrutinize' Novo Nordisk's Bid for Catalent
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,158
Is the side effect of GLP-1 drugs too big? Danish pharmaceutical company Zealand advances "next-generation weight loss drugs"
①Although novo-nordisk a/s and eli lilly and co's drugs are effective in weight loss, the side effects they bring should not be ignored. Currently known side effects include significant muscle loss and increased suicidal thoughts; ②Danish pharmaceutical company Zealand states that a weight loss drug they are developing has higher quality in weight loss - less muscle loss and fewer side effects.
Harris, Trump Tied in Battle for Swing States, WSJ Poll Shows -- WSJ
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000